First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice

The aim is to evaluate the efficacy of the first-line rituximab-containing therapy of B-cell lymphoproliferative diseases in Russian clinical practice between 2014 and 2017. Materials and methods. In the post-authorisation multicenter study EQUILIBRIUM were included 1 thousand patients aged from...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lali G. Babicheva, Irina V. Poddubnaya
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2020
Materias:	non-hodgkin’s lymphoma rituximab follicular lymphoma marginal zone lymphoma routine clinical practice the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a8c86a1abee24252a6ffdffa30b488a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a8c86a1abee24252a6ffdffa30b488a6
record_format	dspace
spelling	oai:doaj.org-article:a8c86a1abee24252a6ffdffa30b488a62021-11-30T17:03:34ZFirst-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice1815-14341815-144210.26442/18151434.2020.2.200125https://doaj.org/article/a8c86a1abee24252a6ffdffa30b488a62020-07-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/34967/23382https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442The aim is to evaluate the efficacy of the first-line rituximab-containing therapy of B-cell lymphoproliferative diseases in Russian clinical practice between 2014 and 2017. Materials and methods. In the post-authorisation multicenter study EQUILIBRIUM were included 1 thousand patients aged from 21 to 91 with B-cell non-Hodgkins lymphoma or chronic lymphatic leukemia who had received at least 4 cycles of rituximab-containing therapy using the drug Acellbia. This article was devoted to the group of indolent non-Hodgkins lymphomas and included 253 patients: follicular lymphoma 51% of cases, marginal zone lymphoma 44% of patients, extremely rare were registered lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia in 3% and in 2% of cases, respectively. The median age in patients with indolent non-Hodgkins lymphomas was 62 years (2191 years). The vast majority of patients were diagnosed with stage IIIIV 190 (75%) of patients. More than 1/2 (53.4%) of patients in routine practice received R-CHOP therapy as a first-line. BR regimen was applied in 15.4% of cases, 14.2% of patients were treated with R-CVP/R-COP. We indicated rare use of rituximab as monotherapy in induction mode only 4.4% of patients. And 2.4% of patients were treated with fludarabine-containing therapy. Results. The final assessment of the effect was carried out after 68 cycles of treatment and as a result the overall effect was more than 90%: the frequency of complete remission was 61%, partial responses 32.9%. The progression admitted only in 17 (6.7%) patients among 253 observed. With a median of 15 months, the median of overall survival and event-free survival was not achieved. Conclusion. The use of the available and appropriate treatment according to the domestic clinical guidelines with the inclusion of the Russian biosimilar anti-CD20 monoclonal antibody Acellbia, demonstrates high direct efficacy and satisfactory long-term treatment results comparable to the retrospective analysis of the previous clinical studies of the original drug rituximab.Lali G. BabichevaIrina V. PoddubnayaIP Habib O.N.articlenon-hodgkin’s lymphomarituximabfollicular lymphomamarginal zone lymphomaroutine clinical practicethe first-line therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 22, Iss 2, Pp 119-125 (2020)
institution	DOAJ
collection	DOAJ
language	RU
topic	non-hodgkin’s lymphoma rituximab follicular lymphoma marginal zone lymphoma routine clinical practice the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-hodgkin’s lymphoma rituximab follicular lymphoma marginal zone lymphoma routine clinical practice the first-line therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lali G. Babicheva Irina V. Poddubnaya First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
description	The aim is to evaluate the efficacy of the first-line rituximab-containing therapy of B-cell lymphoproliferative diseases in Russian clinical practice between 2014 and 2017. Materials and methods. In the post-authorisation multicenter study EQUILIBRIUM were included 1 thousand patients aged from 21 to 91 with B-cell non-Hodgkins lymphoma or chronic lymphatic leukemia who had received at least 4 cycles of rituximab-containing therapy using the drug Acellbia. This article was devoted to the group of indolent non-Hodgkins lymphomas and included 253 patients: follicular lymphoma 51% of cases, marginal zone lymphoma 44% of patients, extremely rare were registered lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia in 3% and in 2% of cases, respectively. The median age in patients with indolent non-Hodgkins lymphomas was 62 years (2191 years). The vast majority of patients were diagnosed with stage IIIIV 190 (75%) of patients. More than 1/2 (53.4%) of patients in routine practice received R-CHOP therapy as a first-line. BR regimen was applied in 15.4% of cases, 14.2% of patients were treated with R-CVP/R-COP. We indicated rare use of rituximab as monotherapy in induction mode only 4.4% of patients. And 2.4% of patients were treated with fludarabine-containing therapy. Results. The final assessment of the effect was carried out after 68 cycles of treatment and as a result the overall effect was more than 90%: the frequency of complete remission was 61%, partial responses 32.9%. The progression admitted only in 17 (6.7%) patients among 253 observed. With a median of 15 months, the median of overall survival and event-free survival was not achieved. Conclusion. The use of the available and appropriate treatment according to the domestic clinical guidelines with the inclusion of the Russian biosimilar anti-CD20 monoclonal antibody Acellbia, demonstrates high direct efficacy and satisfactory long-term treatment results comparable to the retrospective analysis of the previous clinical studies of the original drug rituximab.
format	article
author	Lali G. Babicheva Irina V. Poddubnaya
author_facet	Lali G. Babicheva Irina V. Poddubnaya
author_sort	Lali G. Babicheva
title	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
title_short	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
title_full	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
title_fullStr	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
title_full_unstemmed	First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice
title_sort	first-line therapy of indolent non-hodgkin’s lymphoma in routine clinical practice
publisher	IP Habib O.N.
publishDate	2020
url	https://doaj.org/article/a8c86a1abee24252a6ffdffa30b488a6
work_keys_str_mv	AT laligbabicheva firstlinetherapyofindolentnonhodgkinslymphomainroutineclinicalpractice AT irinavpoddubnaya firstlinetherapyofindolentnonhodgkinslymphomainroutineclinicalpractice
_version_	1718406399632867328

First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice

Ejemplares similares